1 Cash-Heavy Stock with Promising Prospects and 2 We Find Risky

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Not all businesses with cash are winners, and that’s why we built StockStory - to help you separate the good from the bad. That said, here is one company with a net cash position that balances growth with stability and two with hidden risks.

Two Stocks to Sell:

Magnachip (MX)

Net Cash Position: $66.62 million (60.9% of Market Cap)

With its technology found in common consumer electronics such as TVs and smartphones, Magnachip Semiconductor (NYSE:MX) is a provider of analog and mixed-signal semiconductors.

Why Should You Sell MX?

1. Products and services are facing significant end-market challenges during this cycle as sales have declined by 16.2% annually over the last five years
2. Earnings per share have dipped by 16.8% annually over the past five years, which is concerning because stock prices follow EPS over the long term
3. Free cash flow margin dropped by 13 percentage points over the last five years, implying the company became more capital intensive as competition picked up

At $3.04 per share, Magnachip trades at 0.6x forward price-to-sales. Check out our free in-depth research report to learn more about why MX doesn’t pass our bar.

Strategic Education (STRA)

Net Cash Position: $55 million (3.1% of Market Cap)

Formed through the merger of Strayer Education and Capella Education in 2018, Strategic Education (NASDAQ:STRA) is a career-focused higher education provider.

Why Do We Think STRA Will Underperform?

1. Number of international students has disappointed over the past two years, indicating weak demand for its offerings
2. Incremental sales over the last five years were much less profitable as its earnings per share fell by 5.2% annually while its revenue grew
3. Free cash flow margin is projected to show no improvement next year

Strategic Education is trading at $77.27 per share, or 13x forward P/E. If you’re considering STRA for your portfolio, see our FREE research report to learn more.

One Stock to Watch:

Globus Medical (GMED)

Net Cash Position: $293.4 million (2.5% of Market Cap)

With operations spanning 64 countries and a portfolio of over 10 new products launched in 2023 alone, Globus Medical (NYSE:GMED) develops and sells implantable devices, surgical instruments, and technology solutions for spine, orthopedic, and neurosurgical procedures.

Why Are We Fans of GMED?

1. Constant currency growth averaged 21.9% over the past two years, showing it can expand globally regardless of the macroeconomic environment
2. Estimated revenue growth of 12.9% for the next 12 months implies its momentum over the last two years will continue
3. Earnings per share have massively outperformed its peers over the last five years, increasing by 21.6% annually

Globus Medical’s stock price of $88.26 implies a valuation ratio of 21.2x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.

Stocks We Like Even More

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.